source
- Alnylam cuts TTR franchise guidance, market cap loses $10.8B as shares tumble 28%Alnylam announced a reduction in its full-year revenue outlook for its transthyretin (TTR) franchise, trimming the midpoint by $200 million. The company now projects TTR therapy sales of $4.2 bill…
- Apnimed upsizes IPO to $192 million to fund launch of oral sleep‑apnea drugApnimed, a Massachusetts‑based biotech, announced an upsized initial public offering that now includes 12 million shares priced at $16 each, generating $192 million in gross proceeds. This amount e…